Catherine Coste's most recent trade in Biolife Solutions Inc was a trade of 8,170 Common Stock done . Disclosure was reported to the exchange on Feb. 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biolife Soln Inc | Catherine Havlik Coste | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 8,170 | 13,871 (0%) | 0% | - | Common Stock | |
| Biomerica Inc | Catherine Coste | Director | Grant, award, or other acquisition of securities at price $ 0.31 per share. | 13 Dec 2024 | 85,000 | 128,790 (1%) | 0% | 0.3 | 26,350 | Common stock |
| Renalytix Plc ADR | Catherine Havlik Coste | Independent Director | Purchase of securities on an exchange or from another person at price $ 0.09 per share. | 09 Oct 2024 | 279,866 | 279,866 (0%) | 0% | 0.1 | 25,188 | Ords 0.00p |
| Biomerica Inc | Coste Havlik Catherine | Director | 13 Dec 2023 | 75,000 | 75,000 | - | - | Non-qualified stock option | ||
| Biomerica Inc | Havlik Coste Catherine | Director | 07 Dec 2023 | 32,000 | 32,000 | - | - | Non-qualified stock option | ||
| Biomerica Inc | Catherine Coste | Director, Audit Committee Chairperson | Purchase of securities on an exchange or from another person at price $ 2.96 per share. | 26 Jan 2023 | 2,190 | 43,790 (0%) | 0% | 3.0 | 6,482 | Common Stock |